Asset profile
GPC-100
Small molecule
Evidence outlook · lead readout
NCT05561751 · Multiple Myeloma
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05561751: The study randomized 30 patients to two open-label treatment regimens, but it was not blinded and had no placebo or standard-treatment control arm. Its primary endpoint was the proportion achieving a target number of CD34+ cells during leukapheresis, a surrogate mobilization measure, and no results are available to show whether the endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.